Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2021

Open Access 01-12-2021 | Silicosis | Research Article

Distinct metabolic features in the plasma of patients with silicosis and dust-exposed workers in China: a case–control study

Authors: Changjiang Xue, Na Wu, Yali Fan, Jing Ma, Qiao Ye

Published in: BMC Pulmonary Medicine | Issue 1/2021

Login to get access

Abstract

Background

Silicosis is a progressive pneumoconiosis characterized by interstitial fibrosis following exposure to silica dust. The role of metabolic dysregulation in the pathogenesis of silicosis has not been investigated in detail. This study aimed to identify different metabolic features in the plasma of patients with silicosis and dust-exposed workers without silicosis in metabolomics studies.

Methods

Patients with silicosis, dust-exposed workers (DEWs) without silicosis and age-matched healthy controls were recruited in a case–control study. The metabolomics analyses by ultra-high performance liquid chromatography-mass spectrometry were conducted. Distinct metabolic features (DMFs) were identified in the pilot study and were validated in the validation study. The enriched signalling pathways of these DMFs were determined. The ability of DMFs to discriminate among the groups was analysed through receiver operating characteristic (ROC) curves. The correlations between DMFs and clinical features were also explored.

Results

Twenty-nine DMFs and 9 DMFs were detected and had the same trend in the pilot study and the validation study in the plasma of the DEW and silicosis groups, respectively. Sphingolipid metabolism was the major metabolic pathway in the DEWs, and arginine and proline metabolism was associated with silicosis. Twenty DMFs in the DEWs and 3 DMFs in the patients with silicosis showed a discriminatory ability with ROC curve analysis. The abundance of kynurenine was higher in Stage III silicosis than in Stage I or Stage II silicosis. l-arginine and kynurenine were both negatively correlated with the percentage of forced vital capacity predicted in silicosis.

Conclusions

Distinct metabolic features in the plasma of DEWs and the patients with silicosis were found to be different. Sphingolipid metabolism and arginine and proline metabolism were identified as the major metabolic pathway in the DEW and silicosis groups, respectively. l-arginine and kynurenine were correlated with the severity of silicosis.
Appendix
Available only for authorised users
Literature
2.
go back to reference Blanc PD, Annesi-Maesano I, Balmes JR, et al. The occupational burden of nonmalignant respiratory diseases: an official American Thoracic Society and European Respiratory Society Statement. Am J Respir Crit Care Med. 2019;199:1312–34.CrossRef Blanc PD, Annesi-Maesano I, Balmes JR, et al. The occupational burden of nonmalignant respiratory diseases: an official American Thoracic Society and European Respiratory Society Statement. Am J Respir Crit Care Med. 2019;199:1312–34.CrossRef
3.
go back to reference Wu N, Xue C, Yu S, et al. Artificial stone-associated silicosis in China: a prospective comparison with natural stone-associated silicosis. Respirology. 2020;25(5):518–24.CrossRef Wu N, Xue C, Yu S, et al. Artificial stone-associated silicosis in China: a prospective comparison with natural stone-associated silicosis. Respirology. 2020;25(5):518–24.CrossRef
4.
go back to reference Chen W, Liu Y, Wang H, et al. Long-term exposure to silica dust and risk of total and cause-specific mortality in Chinese workers: a cohort study. PLoS Med. 2012;9:e1001206.CrossRef Chen W, Liu Y, Wang H, et al. Long-term exposure to silica dust and risk of total and cause-specific mortality in Chinese workers: a cohort study. PLoS Med. 2012;9:e1001206.CrossRef
5.
go back to reference Castranova V, Vallyathan V. Silicosis and coal workers’ pneumoconiosis. Environ Health Perspect. 2000;108(Suppl 4):675–84.CrossRef Castranova V, Vallyathan V. Silicosis and coal workers’ pneumoconiosis. Environ Health Perspect. 2000;108(Suppl 4):675–84.CrossRef
6.
7.
go back to reference Liu H, Cheng Y, Yang J, et al. BBC3 in macrophages promoted pulmonary fibrosis development through inducing autophagy during silicosis. Cell Death Dis. 2017;8(3):e2657.CrossRef Liu H, Cheng Y, Yang J, et al. BBC3 in macrophages promoted pulmonary fibrosis development through inducing autophagy during silicosis. Cell Death Dis. 2017;8(3):e2657.CrossRef
8.
go back to reference Nardi J, Nascimento S, Goethel G, et al. Inflammatory and oxidative stress parameters as potential early biomarkers for silicosis. Clin Chim Acta. 2018;484:305–13.CrossRef Nardi J, Nascimento S, Goethel G, et al. Inflammatory and oxidative stress parameters as potential early biomarkers for silicosis. Clin Chim Acta. 2018;484:305–13.CrossRef
9.
go back to reference Miao R, Ding B, Zhang Y, et al. Proteomic profiling change during the early development of silicosis disease. J Thorac Dis. 2016;8(3):329–41.CrossRef Miao R, Ding B, Zhang Y, et al. Proteomic profiling change during the early development of silicosis disease. J Thorac Dis. 2016;8(3):329–41.CrossRef
10.
go back to reference Zhu Y, Yao J, Duan Y, et al. Protein expression profile in rat silicosis model reveals upregulation of PTPN2 and its inhibitory effect on epithelial-mesenchymal transition by dephosphorylation of STAT3. Int J Mol Sci. 2020;21(4):1189.CrossRef Zhu Y, Yao J, Duan Y, et al. Protein expression profile in rat silicosis model reveals upregulation of PTPN2 and its inhibitory effect on epithelial-mesenchymal transition by dephosphorylation of STAT3. Int J Mol Sci. 2020;21(4):1189.CrossRef
11.
go back to reference Bo C, Geng X, Zhang J, et al. Comparative proteomic analysis of silica induced pulmonary fibrosis in rats based on tandem mass tag (TMT) quantitation technology. PLoS ONE. 2020;15(10):e0241310.CrossRef Bo C, Geng X, Zhang J, et al. Comparative proteomic analysis of silica induced pulmonary fibrosis in rats based on tandem mass tag (TMT) quantitation technology. PLoS ONE. 2020;15(10):e0241310.CrossRef
12.
go back to reference Xue C, Wu N, Li X, et al. Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study. BMC Pulm Med. 2017;17(1):144.CrossRef Xue C, Wu N, Li X, et al. Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study. BMC Pulm Med. 2017;17(1):144.CrossRef
13.
go back to reference Aksu N, Samadi A, Yalcinkaya A, et al. Evaluation of oxysterol levels of patients with silicosis by LC–MS/MS method. Mol Cell Biochem. 2020;467(1–2):117–25.CrossRef Aksu N, Samadi A, Yalcinkaya A, et al. Evaluation of oxysterol levels of patients with silicosis by LC–MS/MS method. Mol Cell Biochem. 2020;467(1–2):117–25.CrossRef
14.
go back to reference Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016;17:451–9.CrossRef Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016;17:451–9.CrossRef
15.
go back to reference Trujillo E, Davis C, Milner J. Nutrigenomics, proteomics, metabolomics, and the practice of dietetics. J Am Diet Assoc. 2006;106:403–13.CrossRef Trujillo E, Davis C, Milner J. Nutrigenomics, proteomics, metabolomics, and the practice of dietetics. J Am Diet Assoc. 2006;106:403–13.CrossRef
16.
go back to reference Kottmann RM, Kulkarni AA, Smolnycki KA, et al. Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-beta. Am J Respir Crit Care Med. 2012;186:740–51.CrossRef Kottmann RM, Kulkarni AA, Smolnycki KA, et al. Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-beta. Am J Respir Crit Care Med. 2012;186:740–51.CrossRef
17.
go back to reference Kang YP, Lee SB, Lee JM, et al. Metabolic profiling regarding pathogenesis of idiopathic pulmonary fibrosis. J Proteome Res. 2016;15:1717–24.CrossRef Kang YP, Lee SB, Lee JM, et al. Metabolic profiling regarding pathogenesis of idiopathic pulmonary fibrosis. J Proteome Res. 2016;15:1717–24.CrossRef
18.
go back to reference Zhao YD, Yin L, Archer S, et al. Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study. BMJ Open Respir Res. 2017;4(1):e000183.CrossRef Zhao YD, Yin L, Archer S, et al. Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study. BMJ Open Respir Res. 2017;4(1):e000183.CrossRef
19.
go back to reference Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med. 1998;157:1666–80.CrossRef Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med. 1998;157:1666–80.CrossRef
20.
go back to reference International Labour Office. International Classification of Radiographs of Pneumoconiosis, revised. Occupational Safety and Health Series. 2011;22:Rev 2011. International Labour Office. International Classification of Radiographs of Pneumoconiosis, revised. Occupational Safety and Health Series. 2011;22:Rev 2011.
21.
go back to reference Zhao YY, Cheng XL, Lin RC. Lipidomics applications for discovering biomarkers of diseases in clinical chemistry. Int Rev Cell Mol Biol. 2014;313:1–26.CrossRef Zhao YY, Cheng XL, Lin RC. Lipidomics applications for discovering biomarkers of diseases in clinical chemistry. Int Rev Cell Mol Biol. 2014;313:1–26.CrossRef
22.
go back to reference Zehethofer N, Bermbach S, Hagner S, et al. Lipid analysis of airway epithelial cells for studying respiratory diseases. Chromatographia. 2015;78(5–6):403–13.CrossRef Zehethofer N, Bermbach S, Hagner S, et al. Lipid analysis of airway epithelial cells for studying respiratory diseases. Chromatographia. 2015;78(5–6):403–13.CrossRef
23.
go back to reference Farooqui AA. Lipid mediators in the neural cell nucleus: their metabolism, signaling, and association with neurological disorders. Neuroscientist. 2009;15(4):392–407.CrossRef Farooqui AA. Lipid mediators in the neural cell nucleus: their metabolism, signaling, and association with neurological disorders. Neuroscientist. 2009;15(4):392–407.CrossRef
24.
go back to reference Yang Y, Uhlig S. The role of sphingolipids in respiratory disease. Ther Adv Respir Dis. 2011;5(5):325–44.CrossRef Yang Y, Uhlig S. The role of sphingolipids in respiratory disease. Ther Adv Respir Dis. 2011;5(5):325–44.CrossRef
25.
go back to reference Teichgraber V, et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med. 2008;14(4):382–91.CrossRef Teichgraber V, et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med. 2008;14(4):382–91.CrossRef
26.
go back to reference Nixon GF. Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br J Pharmacol. 2009;158(4):982–93.CrossRef Nixon GF. Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br J Pharmacol. 2009;158(4):982–93.CrossRef
27.
go back to reference Yan F, Wen Z, Wang R, et al. Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics. BMC Pulm Med. 2017;17(1):174.CrossRef Yan F, Wen Z, Wang R, et al. Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics. BMC Pulm Med. 2017;17(1):174.CrossRef
28.
go back to reference Tager AM, Lacamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2007;14(1):45–54.CrossRef Tager AM, Lacamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2007;14(1):45–54.CrossRef
29.
go back to reference Rindlisbacher B, Schmid C, Geiser T, et al. Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis—a potential biomarker role for LysoPC. Respir Res. 2018;19(1):7.CrossRef Rindlisbacher B, Schmid C, Geiser T, et al. Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis—a potential biomarker role for LysoPC. Respir Res. 2018;19(1):7.CrossRef
30.
go back to reference Ringseis R, Keller J, Eder K. Mechanisms underlying the anti-wasting effect of l-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies. Eur J Nutr. 2013;52(5):1421–42.CrossRef Ringseis R, Keller J, Eder K. Mechanisms underlying the anti-wasting effect of l-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies. Eur J Nutr. 2013;52(5):1421–42.CrossRef
31.
go back to reference Saborano R, Wongpinyochit T, Totten JD, et al. Metabolic reprogramming of macrophages exposed to Silk, poly(lactic-co-glycolic acid), and silica nanoparticles. Adv Healthc Mater. 2017;6(14):1601240.CrossRef Saborano R, Wongpinyochit T, Totten JD, et al. Metabolic reprogramming of macrophages exposed to Silk, poly(lactic-co-glycolic acid), and silica nanoparticles. Adv Healthc Mater. 2017;6(14):1601240.CrossRef
32.
go back to reference Peruzzi C, Nascimento S, Gauer B, et al. Inflammatory and oxidative stress biomarkers at protein and molecular levels in workers occupationally exposed to crystalline silica. Environ Sci Pollut Res Int. 2019;26(2):1394–405.CrossRef Peruzzi C, Nascimento S, Gauer B, et al. Inflammatory and oxidative stress biomarkers at protein and molecular levels in workers occupationally exposed to crystalline silica. Environ Sci Pollut Res Int. 2019;26(2):1394–405.CrossRef
33.
go back to reference Anlar HG, Bacanli M, İritaş S, et al. Effects of occupational silica exposure on oxidative stress and immune system parameters in ceramic workers in Turkey. J Toxicol Environ Health Part A. 2017;80:688–96.CrossRef Anlar HG, Bacanli M, İritaş S, et al. Effects of occupational silica exposure on oxidative stress and immune system parameters in ceramic workers in Turkey. J Toxicol Environ Health Part A. 2017;80:688–96.CrossRef
34.
go back to reference Selman M, Thannickal VJ, Pardo A, et al. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs. 2004;64(4):405–30.CrossRef Selman M, Thannickal VJ, Pardo A, et al. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs. 2004;64(4):405–30.CrossRef
35.
go back to reference Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142(12 Pt 1):963–7.CrossRef Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142(12 Pt 1):963–7.CrossRef
36.
go back to reference Kitowska K, Zakrzewicz D, Konigshoff M, et al. Functional role and species-specific contribution of arginases in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008;294(1):L34-45.CrossRef Kitowska K, Zakrzewicz D, Konigshoff M, et al. Functional role and species-specific contribution of arginases in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008;294(1):L34-45.CrossRef
37.
go back to reference Maarsingh H, Pera T, Meurs H. Arginase and pulmonary diseases. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(2):171–84.CrossRef Maarsingh H, Pera T, Meurs H. Arginase and pulmonary diseases. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(2):171–84.CrossRef
38.
go back to reference Nagy BM, Nagaraj C, Meinitzer A, et al. Importance of Kynurenine in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2017;313(5):L741-751.CrossRef Nagy BM, Nagaraj C, Meinitzer A, et al. Importance of Kynurenine in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2017;313(5):L741-751.CrossRef
39.
go back to reference Ran N, Pang Z, Gu Y, Pan H, et al. An updated overview of metabolomic profile changes in chronic obstructive pulmonary disease. Metabolites. 2019;9(6):111.CrossRef Ran N, Pang Z, Gu Y, Pan H, et al. An updated overview of metabolomic profile changes in chronic obstructive pulmonary disease. Metabolites. 2019;9(6):111.CrossRef
40.
go back to reference Chen Q, Ruba SD, Ma Y, et al. Serum Metabolite biomarkers discriminate healthy smokers from COPD smokers. PLoS ONE. 2015;10(12):e0143937.CrossRef Chen Q, Ruba SD, Ma Y, et al. Serum Metabolite biomarkers discriminate healthy smokers from COPD smokers. PLoS ONE. 2015;10(12):e0143937.CrossRef
Metadata
Title
Distinct metabolic features in the plasma of patients with silicosis and dust-exposed workers in China: a case–control study
Authors
Changjiang Xue
Na Wu
Yali Fan
Jing Ma
Qiao Ye
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2021
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-021-01462-1

Other articles of this Issue 1/2021

BMC Pulmonary Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.